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osting by EAbstract Background: Phototherapy has remained the standard therapeutic approach for neonatal
hyperbilirubinemia. Oxidative effects of phototherapy on cell membranes and cell components may
have a wide range of potential adverse effects, including enhanced lipid peroxidation and DNA
damage. Apoptosis is an indispensable mechanism for maintaining many cellular functions, includ-
ing cell replication, and removal of damaged cells with high burden of genetic mutations. Many
genes function as apoptosis regulatory genes. Examples of these genes include the BCL2 gene which
is an anti-apoptotic oncogene, and the BAX gene which acts as a promoter of apoptosis.
Objectives: Assess the effect(s) of phototherapy on DNA and on the rate of apoptosis in full term
neonates with hyperbilirubinemia. It comprised 35 neonates with indirect hyperbilirubinemia who
received phototherapy for 48 h, and 20 apparently healthy full term neonates with normal serum
bilirubin level, as a control group. DNA damage was assessed by DNA fragmentation and micro-
nucleus assay. Determination of the anti-apoptotic effect(s) of BCL2 gene was achieved by quanti-
tative assay of its product, (BCL2) protein, by ELISA and BAX gene expression status was assessed
by PCR.
Results: The frequency of micronuclei in circulating lymphocytes of neonates who received photo-
therapy has signiﬁcantly increased before and after phototherapy compared to controls, (p< 0.001;6337676.
(M.A. El-Salam).
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30 M.Y.Z. El-Abdin et al.p< 0 0.00001), respectively. DNA fragmentation in circulating lymphocytes, was signiﬁcantly
higher among cases before and after phototherapy compared to controls (p< 0.0001; p< 0
0.00001). The plasma BCL2 protein was signiﬁcantly lower in the cases before and after photother-
apy compared to controls (p< 0.01; p< 0.01), respectively, and BAX gene expression was signif-
icantly high among cases before and after phototherapy compared to controls.
Conclusions: Geno toxic effects of bilirubin and phototherapy, induce more DNA damage and
enhances apoptosis of exposed cells, probably through down regulation of BCL2 expression and
upregulation of BAX gene expression in neonates with hyperbilirubinemia.
 2012 Ain Shams University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Over 60% of all term newborns develop jaundice in their ﬁrst
days of life [1]. Unconjugated hyperbilirubinemia occurs as a
result of excessive bilirubin formation and inability of neonatal
liver to clear bilirubin rapidly enough from the blood [2]. The
majority of causes of hyperbilirubinemia in the term newborn
are benign and reversible [3]. However, considering the poten-
tially irreversible toxicity of bilirubin on the central nervous
system, treatment should be carried out to eliminate excessive
bilirubin [4].
Since 1950s, phototherapy has been the therapy of choice
for newborns with hyperbilirubinemia [5], yet there are contro-
versial results regarding its effects on DNA damage. It has
been reported that both conventional and intensive photother-
apy cause DNA damage [6], while others found that DNA was
not affected with phototherapy [7], so further studies in this is-
sue are needed.
Phototherapy induces the release of cutaneous reactive
nitrogen species (RNS) and reactive oxygen species (ROS)
[8], and photolysis products are cytotoxic and are associated
with the production of free oxygen radicals [9]. Free radicals
have been shown to initiate apoptotic cell death in many in-vi-
tro and in-vivo experimental models [10,11]. Two major signal-
ing pathways leading to apoptosis have been identiﬁed. One is
mitochondria-dependent and is controlled by suppressing or
inducing genes, such as BCL2 and BAX, respectively [12].
The other is death receptor dependent, involving the interac-
tion of death receptors involving Fas/Fasl interaction recep-
tor-associated death proteases and subsequent activation of
downstream effector caspases [13].
Ultraviolet-induced DNA damage sets in motion a highly
complex well coordinated series of responses. Human cells
use many strategies to protect genomic DNA from accumulat-
ing such lesions. If the damage is extensive, cell cycle progres-
sion is blocked to allow more time for DNA repair. However,
if the damage is irreparable the affected cells undergo apopto-
sis [14].
The BCL2 family of proteins constitutes a critical control
point in apoptosis residing immediately upstream of irrevers-
ible cellular damage, where family members control the release
of apoptogenic factors from the mitochondria. The cardinal
member of this family, BCL2, was originally discovered as
the deﬁning oncogene in follicular lymphoma [15]. There are
two genes (BCL2 and P53) that control the process of apopto-
sis. BCL2 is an oncogene which blocks apoptosis. It can be
called cell death suppressor gene because of its direct regula-
tion of apoptosis. A high concentration of BCL2 protein pro-
tects the cell from apoptosis [16].The aim of the present study was to evaluate outcome
markers of DNA damage and apoptosis induced in circulating
lymphocytes in neonates suffering from hyperbilirubinemia
and receiving phototherapy as the sole treatment. DNA dam-
age was measured in terms of the formation of micronuclei in
circulating lymphocytes, while apoptosis was measured in
terms of plasma DNA fragmentation and plasma BCL2 level
and BAX mRNA expression in circulating lymphocytes.
2. Patients and methods
2.1. Patients
This study was performed on 55 full term neonates in the 1st
two weeks of life. 35 of them (23 males and 12 females) with
indirect hyperbilirubinemia who were admitted in the neonatal
intensive care unit (NICU) and had received phototherapy for
48 h with mean postnatal age 7.4 ± 3.8 days. The other 20
cases (12 males and 8 females) were apparently healthy full
term neonates with normal serum bilirubin levels, with mean
postnatal age of 8 ± 3.2 days as a control group. The number
of cases of physiological jaundice that were included in the
present study was 23 and the percentage of them was 65%
and the number of cases of pathological jaundice was 12 and
the percentage of them was 35%.
All cases were selected from the neonatal intensive care unit
(NICU) of El-Zahraa University hospital and Nasr City Insur-
ance hospital. A formal consent letter from the parents of each
newborn was obtained after explaining to them the whole pro-
cedure. The study was approved by the Ethics Committee of
the Hospital.
Exclusion criteria:
 Premature and low birth weight infants.
 Neonates with (asphyxia and sepsis).
 Infants of diabetic mothers.
 Neonates with congenital anomalies.
 Neonates with cholestatic jaundice.
All cases enrolled in the study have been subjected to the
following:
Full history taking with special emphasis on:
n Maternal medical history of any acute or chronic illness
before or during pregnancy.
n Full postnatal history taking with stress on the onset of
jaundice, duration of phototherapy exposure, type of milk
(breast, formula or both) and jaundice associated
symptoms.
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Neurological examination (neonatal reﬂexes, state of con-
sciousness and abnormal movement) to detect early CNS
damage.
2.2. Routine investigations
Complete Blood Count (C.B.C), total and direct bilirubin, RH
and blood group, reticulocye count, liver enzymes and serum
albumin level.
3. Speciﬁc investigations
(A) Determination of DNA damage by: DNA fragmenta-
tion assay. Micronucleus assay.
(B) Determination of the anti-apoptotic protein (BCL2) by
Elisa technique.
(C) BAX gene messenger RNA expression by RT-PCR.
4. Sampling
4.1. Eight millilitre of peripheral blood was taken before
phototherapy
3 ml was taken in EDTA vacutainer for C.B.C., Reticlocyte
count. 2 ml was taken in plain vacutainer for Serum bilirubin
level (total and direct bilirubin), RH and blood group, Liver
enzymes and serum albumin level and 3 ml was taken in
EDTA vacutainer for DNA fragmentation assay, frequency
of micronuclei, plasma BCL2 level and BAX gene messenger
RNA expression by RT-PCR.
4.2. Five millilitre of peripheral blood was taken after
phototherapy
Three millilitre taken in EDTA vacutainer for:
 DNA fragmentation assay.
 Frequency of micronuclei.
 Plasma BCL2.
 BAX gene messenger RNA expression by RT-PCR.
4.3. Two millilitre taken in plain vacutainer for: assay of serum
bilirubin level
4.3.1. Assay of the frequency of micronuclei
According to standard methods using the cytokinesis block
micronucleus assay, where a duplicate of 1 ml of whole blood
was cultured, and proliferation was stimulated by the addition
of phytohemaglutinin (5 lg/ml) into 15 ml sterile plastic round
bottom tubes containing media 199, 20% fetal calf serum and
anti-biotic. Cells were incubated for 72 h adding cytochalasin
B 24 h before harvesting. Twenty-four hours after the addition
of cytochalasin B, cells were collected and treated with 0.8%
sodium citrate for 3–5 min and then ﬁxed in methanol:acetic
acid (5:1). Fixed cells were dropped gently onto clean micro-
scope slide, air dried and stained with 4% Giemsa (Sigma)
using standard protocols. Slides were scored at 100·magniﬁcation using a Leica Biomed microscope (Germany).
The frequency of micronuclei in circulating lymphocytes was
calculated according to the standard criteria [17].
4.3.2. Assay of DNA fragmentation
The DNA fragmentation assay was performed as described
previously according to the method of [18]. Brieﬂy, plasma leu-
kocyte rich layer was mixed with cell lyses buffer (0.1% Triton
X-100, 5 mM Tris–HCl, pH 8, 20 mM EDTA) and centri-
fuged. Small fragments of DNA were gradient separated from
the precipitate with equal volumes of 2 M NaCl and 5% poly-
ethylene glycol 5000 (Sigma) in ethyl ether and were cooled
and centrifuged. The supernatants were removed and mixed
with an equal volume of Hoechst 33258 in PBS and incubated
for 20 min at room temperature. Fluorescence was determined
at 360 nm excitation and 460 nm emissions. Total DNA was
also determined using Hoechst 33258 as a chromogen
4.3.3. ELISA for BCL2 protein
The amounts of BCL2 in white blood cells homogenate were
determined by a sandwich enzyme linked immunosorbent as-
say (ELISA) using two anti-human BCL2 monoclonal murine
antibodies (Quantikine R & D Systems Inc). The measurement
was as follows: A 96 well plate pre-coated coated with anti-hu-
man BCL2 antibody (10 lg/ml diluted with phosphate buffer
saline, PBS) overnight at 4 C. After washing the plate with
PBS containing 0.05% Tween 20 (T-PBS), the wells were
blocked by skimmed milk solution for 2 h at 37 C. White
blood cells homogenate diluted twice with 1% bovine serum
albumin (BSA)/PBS. Fifty ll of the samples and standard
BCL2 (diluted with 1% BSA/PBS) were added to the well
and incubated for 1 h at room temperature. After washing
with T-PBS, biotinylated NOK-1 anti-human BCL2 antibody
(5 lg/ml containing 5% mouse serum) was added and incu-
bated for 1 h at room temperature. The wells were washed ﬁve
times with T-PBS and incubated with 50 ll tetramethyl benzi-
din (MO, USA) for 1 h at room temperature. Chromegen
activity was detected by absorbance measured at 450 nm using
an ELISA reader.
4.3.4. Reverse transcriptase polymerase chain reaction (RT-
PCR) assay for BAX mRNA
Total RNA was extracted from lymphocytes separated from
the peripheral blood by Ficoll-Hypaque density gradient sepa-
ration using Histopaque-1077 (Sigma Diagnostics, St Louis,
Missouri, USA), using QIAGEN RNeasy extraction Kit
(QIAGEN Inc, USA). The RNA samples were reverse tran-
scribed using Superscript reverse transcriptase, using QIA-
GEN One Step RT-PCR kit (QIAGEN Inc USA, Clini
Lab). The thermal cycler was programed as follows: 30 min
50, 15 min 95, 35 cycles of 3-step cycling 1 min at 94,
1 min at 55 and 1 min at 72 C with ﬁnal extension of 72 C
for 10 min. Bax (13) sequences, forward: 50-CAC CAG CTC
TGA-GCA GAT G-30; reverse: 50-GCG AGG CGG
TGA-GCA CTC C-30). Primers for b-actin were synthesized
simultaneously as an internal reference for all samples (for-
ward: 50-GTG GGG CGC CCC AGG CAC CA-30; reverse:
50-CTC CTT AAT GTC ACG CAC GAT TTC-30). Bax (13)
sequences, forward: 50-CAC CAG CTC TGA-GCA GAT
G-30; reverse: 50-GCG AGG CGG TGA-GCA CTC C-30).
Five ll of RT reaction was mixed with different primers to-
gether with 25 ll of Ready Mix RedTaq PCR reaction mix
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dNTP), with 1.5 units of Taq DNA polymerase (Sigma), 2 ll
of each primer working solution (working concentration of
primers: 50 pM/ll), and PCR grade water to a ﬁnal volume
of 50 ll. For FasL thirty eight cycles of ampliﬁcation were per-
formed in a Perkin Emler thermal cycler After initial denatur-
ation at 95 C for ﬁve minutes, each cycle consisted of
denaturation at 94 C for one minute, annealing at 55 C for
two minutes, and extension at 72 C for three minutes. A ﬁnal
extension step was performed at 72 C for 5 min. Ten lL from
each PCR reaction product was separated on a 1.2% agarose
gel then stained with ehidium bromide The appearance of spe-
ciﬁc bands (Bax 516 bp and b-actin 540 bp) was evaluated un-
der ultraviolet light and photographed.
4.3.5. Statistical analysis
A. Descriptive statistics (arithmetic mean, standard deviation
of the mean) were performed for all cases of the study.
B. The results of the ‘‘t’’-value were checked on student’s
‘‘t’’-table to ﬁnd out the signiﬁcance level (P value) according
to the degree of freedom.
 p> 0.05 = Non signiﬁcant
 p< 0.05 = Signiﬁcant
 p< 0.001 = Highly signiﬁcant
All calculations and data presentations were carried out by
the use of the software Microsoft Excel V.5 (2003).
5. Results
The results of the present study were presented in Tables 1–3
and Figs. 1–4. Comparison between cases and controls regard-
ing CBC, liver enzymes, direct bilirubin and serum albumin
levels showed no statistical signiﬁcant differences. On the other
hand, reticulocyte count showed high statistical signiﬁcant dif-
ferences in the cases before phototherapy compared to controls
(Table 1).
Comparison between cases and controls regarding serum
bilirubin level, there were signiﬁcantly higher levels among
cases before phototherapy compared to controls. After photo-
therapy it became signiﬁcantly lower compared to its level be-
fore phototherapy (Table 2).Table 1 Comparison of CBC, reticulocytic count, liver enzymes,
controls.
Variable Control n= 20
Mean ± SD
White blood cell count · 109/l 7.900 ± 1.796
RBC · 106 mm3 4.43 ± 0.53
HB g/dl 14.550 ± 1.504
Hematocrit% 42.650 ± 4.580
Platelets · 109/l 266.600 ± 86.408
Reticlocytic% 1.000 ± 0.000
SGOT U/L 44.500 ± 2.188
SGPT U/L 43.900 ± 2.269
Direct bilirubin mg/dl 0.7 ± 0.5
Serum albumin mg/dl 3.38 ± 0.19
* P> 0.05 (NS).There is a signiﬁcant increase in DNA fragmentation in cir-
culating lymphocytes among cases compared to controls. After
phototherapy it showed more statistical signiﬁcant increase in
DNA fragmentation compared to its level before phototherapy
among cases (Table 2, Fig. 1).
There is signiﬁcant increase in frequency of micronuclei in
circulating lymphocytes among cases compared to controls.
After phototherapy the level of the frequency of micronuclei
in circulating lymphocytes became highly signiﬁcant compared
to its level before phototherapy (Table 2, Figs. 2 and 3).
Plasma BCL2 protein level was signiﬁcantly lower among
cases before phototherapy compared to controls. After photo-
therapy it became more signiﬁcantly lower compared to its le-
vel before phototherapy (Table 3, Fig. 4).
BAX messenger RNA expression was signiﬁcantly higher
among cases before phototherapy compared to controls, after
phototherapy BAX messenger RNA expression was more sig-
niﬁcantly higher (Table 3).
6. Discussion
Although adverse effects of phototherapy have been evaluated
clinically in several studies, information on the potential cellu-
lar effects of phototherapy such as DNA damage is limited
[19]. The study of DNA at the chromosome level is an essential
part of genetic toxicology, because chromosomal mutations
are important events in carcinogenesis. Micronucleus assays
have emerged as one of the preferred methods for assessing
chromosome damage or loss and chromosome breakage to
be measured reliably [20]. Micronuclei are morphologically
similar to main nuclei but smaller in size, hence the name
[21], in the present study by both micronucleus and DNA frag-
mentation assays, we had detected the DNA damage.
Although very high levels of bilirubin are known to be
toxic, there is continued uncertainty about the risks and bene-
ﬁts of moderate serum bilirubin concentrations [22]. In the
present study we found that high level of bilirubin is associated
with DNA damage in peripheral lymphocyte as there was sta-
tistically signiﬁcant difference between DNA damage in cases
before phototherapy compared to controls. On the other hand
Dani et al. described the antioxidant properties of bilirubin.
He showed that bilirubin in micromolar concentrations has
stronger antioxidant effects than vitamin E [23].direct bilirubin and serum albumin between the cases and the
Cases n= 35 t-test
Mean ± SD t P-value
7.825 ± 2.111 0.121 0.904*
3.95 ± 1.09 1.771 0.0846*
13.125 ± 3.149 1.826 0.076*
38.950 ± 8.532 1.709 0.096*
272.700 ± 91.435 0.217 0.829*
2.300 ± 0.470 2.854 0.007*
43.750 ± 2.531 1.002 0.323 *
44.100 ± 2.174 0.285 0.777*
0.6 ± 0.4 0.425 0.324*
3.38 ± 0.22 0.00 1.00*
Table 2 Comparison of serum bilirubin, DNA fragmentations and frequency of micronuclei in circulating lymphocytes between
control and case also among studied cases before and after phototherapy.
Cases n= 35 Control n= 20 t-test
Mean ± SD Mean ± SD t P-value
Serum bilirubin level mg/dl
Before phototherapy 14.600 ± 4.300 1.300 ± 0.400 13.773 <0.001*
After phototherapy 6.824 ± 2.099 1.300 ± 0.400 11.561
Paired t-test t 9.986
P-value <0.001*
DNA fragmentation
Before phototherapy 1.400 ± 0.400 0.800 ± 0.070 6.6 <0.0001**
After phototherapy 3.400 ± 0.800 0.800 ± 0.070 4.4 <0.00001**
Paired t-test t-test 9.233
P-value <0.00001**
Frequency of micronuclei in circulating lymphocytes in full term neonates with hyperbilirubinemia
Before phototherapy 5.500 ± 2.800 2.800 ± 0.400 4.5 <0.001**
After phototherapy 7.800 ± 1.200 2.800 ± 0.400 12.5 <0.00001**
Paired t-test t-test 6.845
P-value <0.001**
* P 6 0.05 (signiﬁcant).
** P 6 0.01 (highly signiﬁcant).
Table 3 Comparison of plasma BCL2 Protein levels and Bax mRNA Expression between cases before and after phototherapy
compared to controls.
BCL2 Protein ng/ml Cases n= 35
Mean ± SD
Control n= 20
Mean ± SD
t-test
t P-value
Before phototherapy 8.600 ± 2.400 11.800 ± 4.200 3.1 0.01*
After phototherapy 4.800 ± 1.800 11.800 ± 4.200 5.4 0.01*
Paired t-test t-test 5.156
P-value <0.001*
Bax mRNA expression
Before phototherapy 0.14 ± 0.1 0.08 ± 0.01 5.3 0.01*
After phototherapy 0.39 ± 0.12 0.08 ± 0.01 6.7 0.01*
Paired t-test t-test 22.656
P-value <0.001*
* P 6 0.01 (highly signiﬁcant).
Figure 1 DNA fragmentation in the study group before and
after phototherapy compared to controls. Figure 2 Frequency of micronuclei among cases before and after
phototherapy compared to controls.
Phototherapy and DNA changes in full term neonates with hyperbilirubinemia 33In the present study we had found that both phototherapy
and high serum bilirubin levels can lead to DNA damage as
there was a highly signiﬁcant difference between cases beforephototherapy and controls. After phototherapy exposure
DNA damage had signiﬁcantly increased in the cases. Our
ﬁndings are in agreement with Krakukcu et al. who showed
Figure 3 Binucleated cell showing one micronucleus.
Figure 4 BCL2 Protein level in the cases before and after
phototherapy compared to the controls.
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newborns as photochemical reactions may produce toxic
photoproducts, probably peroxides [4]. Similarly Dani et al. re-
ported that membrane bound bilirubin is a photo sensitizer as
it captures light energy and becomes energized to its triplet
state. This photo-excited molecule can transfer its energy to
molecular oxygen, singlet oxygen and becomes a highly reac-
tive radical that can oxidize tissues at the molecular level [24].
Aycicek et al studied DNA-damaging effects of intensive
and conventional phototherapy by the comet assay and com-
pared results with the control group [6]. The main outcome
of this study was that endogenous mononuclear leukocyte
DNA strand-breaks had signiﬁcantly increased in both con-
ventional and intensive phototherapy-treated infants when
compared with controls that did not receive phototherapy.
He believed that bilirubin is more active as an oxidant than
its photo-excited form and the waste products are formed by
phototherapy. In contrast to the present results Krakukcu
et al. found that phototherapy does not stimulate or enhance
the DNA-damaging effects of bilirubin as their results indicate
that the DNA damage in infants receiving phototherapy was
not different from that in the control group [4]. As in vivo con-
ditions, phototherapy does not cause an increase in DNA oxi-
dation by itself, in contrast to its effects in vitro as the situation
in vivo is different from that in vitro, as the phototherapy lightis ﬁltered through tissues. Although DNA damage is induced
in human cells through exposure to phototherapy light, it is
clear that these alterations do not result in immediate or wide-
spread harmful consequences because thousands of babies
have been treated with phototherapy since 1958 and no serious
side effects have been noticed [25].
In spite of this observation it is wise to avoid unnecessary use
of neonatal phototherapy as unwanted effects on DNA have
been demonstrated in both peripheral lymphocytes and mono-
nuclear leukocytes in term infant [6,26]. And also our study
showed that phototherapy causes unfortunate effects on
DNA, and also long term follow up studies are recommended.
Interestingly, a recent study including patients with more than
a 30-year follow up period has shown that neonatal photother-
apy is associated with allergic rhinitis and conjunctivitis [27]. In
this study, we have assessed the role of BCL2 protein as an anti-
apoptotic protein and assessed bax gene expression in peripheral
blood lymphocytes induced by phototherapy exposure in neo-
born with hyperbilirubinemia. We found that our ﬁndings are
in agreement with [28] who reported that among the effects of
phototherapy noted was increase in apoptosis of polymorpho-
nuclear cells which leads to decreased number of neutrophils
in areas of inﬂammation and neutrophil anti-apoptotic factors.
In the present study, we found that the level of BCL2 Pro-
tein was lower among the cases compared to controls. After
phototherapy it became signiﬁcantly lower compared to its le-
vel before phototherapy in the cases. El-Haddidi et al who
studied the effect of PUVA phototherapy on BCL2 level in
dermal lymphocytes, found that PUVA phototherapy induces
evident down regulation of BCL2 level and causes early signif-
icant depletion of epidermal and dermal T cells in psoriatic
tissues via the induction of apoptosis [19]. Finally, the
hematopoietic system, particularly the lymphoid lineage, is
highly susceptible to DNA damage and organisms rely on
apoptosis for the removal of damaged cells. Excess BCL2
overcomes the apoptosis inducing the effect of P53 protein,
so the alleviation of cell cycle arrest by a decreased level of
BCL2, potentiates P53 induced apoptosis [29].
Members of the Bcl2 family of proteins are important reg-
ulators of programed cell death pathways with individual
members that can suppress (e.g., BCL2, BCL-XL) or promote
(e.g., BAX, BAD) apoptosis [30]. The BAX and BCL2 are the
key players of this family [31]. We evaluated the effect of pho-
totherapy treatment on the levels of BAX protein expression
and we found that BAX gene expression in peripheral lympho-
cytes was signiﬁcantly higher compared to controls before pho-
totherapy. After phototherapy, it showed more signiﬁcant
increase, suggesting an apoptotic role through a concomitant
decrease in BCL2 levels.
We reported increased DNA damage and a concomitant in-
crease of rate of apoptosis. This might be explained by BCL2
down regulation and increased BAX gene expression. How-
ever, this does not guarantee that all damaged cells will under-
go apoptosis. The concept of survival at the expense of
proliferation awaits further validation as more mechanistic
data come to light.
7. Conclusions
This study is another proof of the geno toxic effects of both
bilirubin and phototherapy. High bilirubin level is toxic in neo-
nates as it induces DNA damage. Phototherapy was found to
Phototherapy and DNA changes in full term neonates with hyperbilirubinemia 35induce more DNA damage than that was induced by high bil-
irubin level. Phototherapy seems to induce an evident down
regulation of BCL2 level in newborn with hyperbilirubinemia
as BCL2 and upregulation of BAX gene expression in neonates
with hyperbilirubinemia
8. Recommendations
Restriction of the use of phototherapy only in serious cases of
hyperbilirubinemia considering risks and beneﬁts is according
to the guidelines of American Academy of Pediatrics. Long
term follow up studies are recommended for the jaundiced
babies who were exposed to phototherapy.
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